MetaCap

Progyny Inc. (PGNY)

NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD

35.71+0.26 (+0.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PGNY stock chart

Technical analysis

Key statistics

All statistics
52-week range
16.10 – 37.21
Day range
35.50 – 36.07
Volume / Avg
1.11M / 1.10M
Beta
—

52-week range

$16.10$37.21

PGNY stock today

Progyny (PGNY) closed at $35.71 on Nov 20, up 0.73% (+$0.26), versus the S&P 500's 3.70% decline. At this level, PGNY sits near the top of its 52-week range of $16.10 to $37.21: 4.0% below the high, set on Nov 16, 2026 and 121.8% above the low. PGNY is up 39.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.1%.

At 32.8x trailing earnings, Progyny trades above the peer-group median of 22.4x. Its forward P/E of 14.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Progyny

Company profile

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.

Industry
Misc Health and Biotechnology Services
CEO
Mr. Peter Anevski CPA
Headquarters
New York, NY
Employees
835
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Progyny generated $1.29 billion in revenue, up 10.4% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $58.5 million (+7.7% year over year), for a net margin of 4.5% versus a median of 5.7% in the prior 5 years. Gross margin was 23.6% (up from 21.7%) and operating margin 6.6%.

Progyny annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.29B$1.17B$1.09B$786.91M$500.62M
Growth+10.40%+7.22%+38.34%+57.19%+45.17%
Net income$58.52M$54.34M$62.04M$30.36M$65.77M
EPS (diluted)$0.65$0.57$0.62$0.30$0.66

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$37.75+5.71%

  • Strong buy 1
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $35.00High $42.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.15 vs $0.27
Surprise
-44.44%

PGNY news

All PGNY news

Progyny peers

Health Care sector
PGNY peer companies
CompanyPrice% ChgMarket capCompare
AGLagilon health inc.90.24+0.83%$1.52Bvs PGNY
SHCSotera Health Company15.91-1.85%$4.54Bvs PGNY
VMDViemed Healthcare Inc.8.52-1.05%$322.85Mvs PGNY
PARKPark Dental Partners Inc.17.03-6.79%$94.26Mvs PGNY
CCELCryo-Cell International Inc.4.150.00%$33.46Mvs PGNY
MGRXMangoceuticals Inc.0.1236-7.55%$2.75Mvs PGNY
NIVFNewGenIvf Group Limited Class A0.0269-23.14%$80.77Kvs PGNY
DVADaVita Inc.161.03+3.00%$10.13Bvs PGNY

Indexes, lists and sector

Progyny stock FAQ

What is Progyny's stock price today?

PGNY last traded at $35.71 as of Nov 20, 4:00 PM EST, up 0.73% on the day. Prices are delayed at least 15 minutes.

What is PGNY's P/E ratio?

PGNY trades at a trailing P/E ratio of 32.76 and a forward P/E of 14.87, compared with a median of 22.4 for its closest peers.

Who is Progyny's CEO?

Mr. Peter Anevski CPA is the chief executive officer of Progyny Inc., which has about 835 employees.

What is the PGNY 52-week high?

The 52-week high for PGNY is $37.21 and the 52-week low is $16.10. The stock is currently 4.0% below its high.

Compare PGNY